Sage Therapeutics announced interim, topline results from a July data cut of the ongoing Phase 3 open-label SHORELINE Study. This […]
Axsome Therapeutics announced top-line results from the phase 3 STRIDE-1 trial evaluating AXS-05 versus active comparator bupropion for treatment of […]
Over the past decade, many scholars have questioned the credibility of research across a variety of scientific fields. Some of […]
The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the U.S. Food and Drug Administration (FDA) has agreed to […]
New York University School of Medicine researchers are in hot pursuit of demonstrating how Artificial Intelligence (AI) can detect post-traumatic […]
